Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer
Ovarian cancer is the seventh most frequent cancer diagnosis worldwide, and the eighth leading cause of cancer mortality. Epithelial ovarian cancer is the most common kind, accounting for 90% of cases. First-line therapy for women with epithelial ovarian cancer consists of a combination of cytoreduc...
Saved in:
Published in | Cochrane database of systematic reviews Vol. 7; p. CD008766 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
12.07.2022
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Ovarian cancer is the seventh most frequent cancer diagnosis worldwide, and the eighth leading cause of cancer mortality. Epithelial ovarian cancer is the most common kind, accounting for 90% of cases. First-line therapy for women with epithelial ovarian cancer consists of a combination of cytoreductive surgery and platinum and taxane-based chemotherapy. However, more than 50% of women with epithelial ovarian cancer will experience a relapse and require further chemotherapy and at some point develop resistance to platinum-based drugs. Currently, guidance on the use of most chemotherapy drugs, including taxanes, is unclear for women whose epithelial ovarian cancer has recurred. Paclitaxel, topotecan, pegylated liposomal doxorubicin hydrochloride, trabectedin and gemcitabine are all licensed for use in the UK at the discretion of clinicians, following discussion with the women as to potential adverse effects. Taxanes can be given in once-weekly regimens (at a lower dose) or three-weekly regimens (at a higher dose), which may have differences in the severity of side effects and effectiveness. As relapsed disease suggests incurable disease, it is all the more important to consider side effects and the impact of treatment schedules, as well as quality of life, and not only the life-prolonging effects of treatment.
To assess the efficacy and toxicity of different taxane monotherapy regimens for women with recurrent epithelial ovarian, tubal or primary peritoneal cancer.
We searched CENTRAL, MEDLINE and Embase, up to 22 March 2022. Other related databases and trial registries were searched as well as grey literature and no additional studies were identified. A total of 1500 records were identified.
We included randomised controlled trials of taxane monotherapy for adult women diagnosed with recurrent epithelial ovarian, tubal or primary peritoneal cancer, previously treated with platinum-based chemotherapy. We included trials comparing two or more taxane monotherapy regimens. Participants could be experiencing their first recurrence of disease or any line of recurrence.
Two review authors screened, independently assessed studies, and extracted data from the included studies. The clinical outcomes we examined were overall survival, response rate, progression-free survival, neurotoxicity, neutropenia, alopecia, and quality of life. We performed statistical analyses using fixed-effect and random-effects models following standard Cochrane methodology. We rated the certainty of evidence according to the GRADE approach.
Our literature search yielded 1500 records of 1466 studies; no additional studies were identified by searching grey literature or handsearching. We uploaded the search results into Covidence. After the exclusion of 92 duplicates, we screened titles and abstracts of 1374 records. Of these, we identified 24 studies for full-text screening. We included four parallel-group randomised controlled trials (RCTs). All trials were multicentred and conducted in a hospital setting. The studies included 981 eligible participants with recurrent epithelial ovarian cancer, tubal or primary peritoneal cancer with a median age ranging between 56 to 62 years of age. All participants had a WHO (World Health Organization) performance status of between 0 to 2. The proportion of participants with serous histology ranged between 56% to 85%. Participants included women who had platinum-sensitive (71%) and platinum-resistant (29%) relapse. Some participants were taxane pre-treated (5.6%), whilst the majority were taxane-naive (94.4%). No studies were classified as having a high risk of bias for any of the domains in the Cochrane risk of bias tool. We found that there may be little or no difference in overall survival (OS) between weekly paclitaxel and three-weekly paclitaxel, but the evidence is very uncertain (risk ratio (RR) of 0.94, 95% confidence interval (CI) 0.66 to 1.33, two studies, 263 participants, very low-certainty evidence). Similarly, there may be little or no difference in response rate (RR of 1.07, 95% CI 0.78 to 1.48, two studies, 263 participants, very low-certainty evidence) and progression-free survival (PFS) (RR of 0.83, 95% CI 0.46 to 1.52, two studies, 263 participants, very low-certainty evidence) between weekly and three-weekly paclitaxel, but the evidence is very uncertain. We found differences in the chemotherapy-associated adverse events between the weekly and three-weekly paclitaxel regimens. The weekly paclitaxel regimen may result in a reduction in neutropenia (RR 0.51, 95% 0.27 to 0.95, two studies, 260 participants, low-certainty evidence) and alopecia (RR 0.58, 95% CI 0.46 to 0.73, one study, 205 participants, low-certainty evidence). There may be little or no difference in neurotoxicity, but the evidence was very low-certainty and we cannot exclude an effect (RR 0.53, 95% CI 0.19 to 1.45, two studies, 260 participants). When examining the effect of paclitaxel dosage in the three-weekly regimen, the 250 mg/m
paclitaxel regimen probably causes more neurotoxicity compared to the 175 mg/m
regimen (RR 0.41, 95% CI 0.21 to 0.80, one study, 330 participants, moderate-certainty evidence). Quality-of-life data were not extractable from any of the included studies.
Fewer people may experience neutropenia when given weekly rather than three-weekly paclitaxel (low-certainty evidence), although it may make little or no difference to the risk of developing neurotoxicity (very low-certainty evidence). This is based on the participants receiving lower doses of drug more often. However, our confidence in this result is low and the true effect may be substantially different from the estimate of the effect. Weekly paclitaxel probably reduces the risk of alopecia, although the rates in both arms were high (46% versus 79%) (low-certainty evidence). A change to weekly from three-weekly chemotherapy could be considered to reduce the likelihood of toxicity, as it may have little or no negative impact on response rate (very low-certainty evidence), PFS (very low-certainty evidence) or OS (very low-certainty evidence). Three-weekly paclitaxel, given at a dose of 175 mg/m
compared to a higher dose,probably reduces the risk of neurotoxicity.We are moderately confident in this result; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. A change to 175 mg/m
paclitaxel (from a higher dose), if a three-weekly regimen is used, probably has little or no negative impact on PFS or OS (very low-certainty evidence). |
---|---|
AbstractList | Ovarian cancer is the seventh most frequent cancer diagnosis worldwide, and the eighth leading cause of cancer mortality. Epithelial ovarian cancer is the most common kind, accounting for 90% of cases. First-line therapy for women with epithelial ovarian cancer consists of a combination of cytoreductive surgery and platinum and taxane-based chemotherapy. However, more than 50% of women with epithelial ovarian cancer will experience a relapse and require further chemotherapy and at some point develop resistance to platinum-based drugs. Currently, guidance on the use of most chemotherapy drugs, including taxanes, is unclear for women whose epithelial ovarian cancer has recurred. Paclitaxel, topotecan, pegylated liposomal doxorubicin hydrochloride, trabectedin and gemcitabine are all licensed for use in the UK at the discretion of clinicians, following discussion with the women as to potential adverse effects. Taxanes can be given in once-weekly regimens (at a lower dose) or three-weekly regimens (at a higher dose), which may have differences in the severity of side effects and effectiveness. As relapsed disease suggests incurable disease, it is all the more important to consider side effects and the impact of treatment schedules, as well as quality of life, and not only the life-prolonging effects of treatment.
To assess the efficacy and toxicity of different taxane monotherapy regimens for women with recurrent epithelial ovarian, tubal or primary peritoneal cancer.
We searched CENTRAL, MEDLINE and Embase, up to 22 March 2022. Other related databases and trial registries were searched as well as grey literature and no additional studies were identified. A total of 1500 records were identified.
We included randomised controlled trials of taxane monotherapy for adult women diagnosed with recurrent epithelial ovarian, tubal or primary peritoneal cancer, previously treated with platinum-based chemotherapy. We included trials comparing two or more taxane monotherapy regimens. Participants could be experiencing their first recurrence of disease or any line of recurrence.
Two review authors screened, independently assessed studies, and extracted data from the included studies. The clinical outcomes we examined were overall survival, response rate, progression-free survival, neurotoxicity, neutropenia, alopecia, and quality of life. We performed statistical analyses using fixed-effect and random-effects models following standard Cochrane methodology. We rated the certainty of evidence according to the GRADE approach.
Our literature search yielded 1500 records of 1466 studies; no additional studies were identified by searching grey literature or handsearching. We uploaded the search results into Covidence. After the exclusion of 92 duplicates, we screened titles and abstracts of 1374 records. Of these, we identified 24 studies for full-text screening. We included four parallel-group randomised controlled trials (RCTs). All trials were multicentred and conducted in a hospital setting. The studies included 981 eligible participants with recurrent epithelial ovarian cancer, tubal or primary peritoneal cancer with a median age ranging between 56 to 62 years of age. All participants had a WHO (World Health Organization) performance status of between 0 to 2. The proportion of participants with serous histology ranged between 56% to 85%. Participants included women who had platinum-sensitive (71%) and platinum-resistant (29%) relapse. Some participants were taxane pre-treated (5.6%), whilst the majority were taxane-naive (94.4%). No studies were classified as having a high risk of bias for any of the domains in the Cochrane risk of bias tool. We found that there may be little or no difference in overall survival (OS) between weekly paclitaxel and three-weekly paclitaxel, but the evidence is very uncertain (risk ratio (RR) of 0.94, 95% confidence interval (CI) 0.66 to 1.33, two studies, 263 participants, very low-certainty evidence). Similarly, there may be little or no difference in response rate (RR of 1.07, 95% CI 0.78 to 1.48, two studies, 263 participants, very low-certainty evidence) and progression-free survival (PFS) (RR of 0.83, 95% CI 0.46 to 1.52, two studies, 263 participants, very low-certainty evidence) between weekly and three-weekly paclitaxel, but the evidence is very uncertain. We found differences in the chemotherapy-associated adverse events between the weekly and three-weekly paclitaxel regimens. The weekly paclitaxel regimen may result in a reduction in neutropenia (RR 0.51, 95% 0.27 to 0.95, two studies, 260 participants, low-certainty evidence) and alopecia (RR 0.58, 95% CI 0.46 to 0.73, one study, 205 participants, low-certainty evidence). There may be little or no difference in neurotoxicity, but the evidence was very low-certainty and we cannot exclude an effect (RR 0.53, 95% CI 0.19 to 1.45, two studies, 260 participants). When examining the effect of paclitaxel dosage in the three-weekly regimen, the 250 mg/m
paclitaxel regimen probably causes more neurotoxicity compared to the 175 mg/m
regimen (RR 0.41, 95% CI 0.21 to 0.80, one study, 330 participants, moderate-certainty evidence). Quality-of-life data were not extractable from any of the included studies.
Fewer people may experience neutropenia when given weekly rather than three-weekly paclitaxel (low-certainty evidence), although it may make little or no difference to the risk of developing neurotoxicity (very low-certainty evidence). This is based on the participants receiving lower doses of drug more often. However, our confidence in this result is low and the true effect may be substantially different from the estimate of the effect. Weekly paclitaxel probably reduces the risk of alopecia, although the rates in both arms were high (46% versus 79%) (low-certainty evidence). A change to weekly from three-weekly chemotherapy could be considered to reduce the likelihood of toxicity, as it may have little or no negative impact on response rate (very low-certainty evidence), PFS (very low-certainty evidence) or OS (very low-certainty evidence). Three-weekly paclitaxel, given at a dose of 175 mg/m
compared to a higher dose,probably reduces the risk of neurotoxicity.We are moderately confident in this result; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. A change to 175 mg/m
paclitaxel (from a higher dose), if a three-weekly regimen is used, probably has little or no negative impact on PFS or OS (very low-certainty evidence). |
Author | Stordal, Britta K Doherty, Ben Hall, Neville Patel, Aashna Busschots, Steven Kapros, Evangelos Lawlor, Denise Kalachand, Roshni |
Author_xml | – sequence: 1 givenname: Aashna surname: Patel fullname: Patel, Aashna organization: Department of Natural Sciences, Middlesex University, London, UK – sequence: 2 givenname: Roshni surname: Kalachand fullname: Kalachand, Roshni organization: Department of Medical Oncology, Beaumont Hospital and Royal College of Surgeons in Ireland, Dublin 9, Ireland – sequence: 3 givenname: Steven surname: Busschots fullname: Busschots, Steven organization: Department of Histopathology, St James Hospital and Trinity College Dublin, Dublin 8, Ireland – sequence: 4 givenname: Ben surname: Doherty fullname: Doherty, Ben organization: Department of Histopathology, St James Hospital and Trinity College Dublin, Dublin 8, Ireland – sequence: 5 givenname: Evangelos surname: Kapros fullname: Kapros, Evangelos organization: Department of Computer Science, Trinity College Dublin, Dublin 2, Ireland – sequence: 6 givenname: Denise surname: Lawlor fullname: Lawlor, Denise organization: Department of Histopathology, St James Hospital and Trinity College Dublin, Dublin 8, Ireland – sequence: 7 givenname: Neville surname: Hall fullname: Hall, Neville organization: Department of Natural Sciences, Middlesex University, London, UK – sequence: 8 givenname: Britta K surname: Stordal fullname: Stordal, Britta K organization: Department of Natural Sciences, Middlesex University, London, UK |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35866378$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j91KxDAUhIMo7o--wpIXaE2a5u9SVl2FBW8qeLecpqdaaZOSdsV9eyPq1WHmmzkwK3Lug0dCNpzlnLHihpdKciNNvr1jzGil8vFYizOyTMBmpRWvC7Kapg_GhOXcXJKFkEYpoc2SVBV8gUc6BB_md4wwnmjEt25AP9E2RJpMOkeEOTkzDW2i7hjjj8CxS7TvoKfhE2IHnjrwDuMVuWihn_D6767Jy8N9tX3M9s-7p-3tPnOlFiLjzrHCWMmt5m1pkSlZCyyYgwbKmikDrQWsTSNr2SiWEkJLJXUjpbWpWKzJ5vdv2jtgcxhjN0A8Hf7nFd8OklSS |
CitedBy_id | crossref_primary_10_2147_CMAR_S457221 crossref_primary_10_2147_IJN_S455942 crossref_primary_10_2298_VSP231201024G |
ContentType | Journal Article |
Copyright | Copyright © 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. |
Copyright_xml | – notice: Copyright © 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1002/14651858.CD008766.pub3 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1469-493X |
ExternalDocumentID | 35866378 |
Genre | Review Research Support, Non-U.S. Gov't Systematic Review Journal Article |
GroupedDBID | --- 53G 5GY 7PX 9HA ABJNI ACGFO ACGFS AENEX ALMA_UNASSIGNED_HOLDINGS ALUQN AYR CGR CUY CVF D7G ECM EIF HYE NPM OEC OK1 P2P RWY WOW ZYTZH |
ID | FETCH-LOGICAL-c4733-1cc028951971f49e065b3e20cada4b068af9aeb8d5b5d6049e375657d55992892 |
IngestDate | Sat Sep 28 08:14:27 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Language | English |
License | Copyright © 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c4733-1cc028951971f49e065b3e20cada4b068af9aeb8d5b5d6049e375657d55992892 |
OpenAccessLink | https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008766.pub3 |
PMID | 35866378 |
ParticipantIDs | pubmed_primary_35866378 |
PublicationCentury | 2000 |
PublicationDate | 2022-07-12 |
PublicationDateYYYYMMDD | 2022-07-12 |
PublicationDate_xml | – month: 07 year: 2022 text: 2022-07-12 day: 12 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Cochrane database of systematic reviews |
PublicationTitleAlternate | Cochrane Database Syst Rev |
PublicationYear | 2022 |
SSID | ssj0039118 |
Score | 2.4614565 |
SecondaryResourceType | review_article |
Snippet | Ovarian cancer is the seventh most frequent cancer diagnosis worldwide, and the eighth leading cause of cancer mortality. Epithelial ovarian cancer is the most... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | CD008766 |
SubjectTerms | Adult Alopecia - drug therapy Bridged-Ring Compounds Carcinoma, Ovarian Epithelial - drug therapy Female Humans Middle Aged Neoplasm Recurrence, Local - drug therapy Neutropenia Ovarian Neoplasms - drug therapy Paclitaxel - adverse effects Taxoids - adverse effects |
Title | Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer |
URI | https://www.ncbi.nlm.nih.gov/pubmed/35866378 |
Volume | 7 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBbpBqUvY1tvu6KHvRV3tiXb8uNINspGyh5S6FuRZIkU2jgkaWn7D_qvd44kXwjpWPdighTLRufzuelcCPliTGJ1XJWRTHUVcZBxUclEFlmdK5R_mXWllMan-ckZ_3menQ8Gj72opZuVOtYPG_NK_oeqMAZ0xSzZZ1C2XRQG4DfQF65AYbj-G43lnQQlEZ4X8qjuj7DRwjWYpm34YBdJDmrhAr3rrh6TmWMyxhX6y-tbsJfhM9cIgEVfWx3WerrAJ2AcKco7XGO99nOnlf8GvdWf-cvldNby-1_ySmJ-sQ_tqWHqsnUC3CzRul4tQ8DZbZeYNqqnWPbX4S-MBudE6gJZQ1i08QwVzO-Il67nb8txix7HHI5cVbx8Izv35WET7NcuMnHc_Behyvo3AFnm147ILBOgQ_muQH-fXSuz3Uxtka1CIKs8RbePF-kMJIJo0svj9OvmF9oh280iazaK01Umr8mrYGTQbx4xb8jAzN6S7XEIo9glEw8c2gMObYBDATgUBmkLHFpb2gKHdsChATjUA2ePnP34PhmeRKG9RqR5wViUaI3HzJi5nFheGlBGFTNprGUluYpzIW0pjRJVprIqB0vSsAIPySssUgc3pvvkxayemUNCleDKSsZzWITLJFXWmgq2yIhYq7TQ78iB34-Lua-hctHs1PsnZz6QnQ5RH8lLCx-t-QQa4Ep9dtT5AwTDXfE |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Taxane+monotherapy+regimens+for+the+treatment+of+recurrent+epithelial+ovarian+cancer&rft.jtitle=Cochrane+database+of+systematic+reviews&rft.au=Patel%2C+Aashna&rft.au=Kalachand%2C+Roshni&rft.au=Busschots%2C+Steven&rft.au=Doherty%2C+Ben&rft.date=2022-07-12&rft.eissn=1469-493X&rft.volume=7&rft.spage=CD008766&rft_id=info:doi/10.1002%2F14651858.CD008766.pub3&rft_id=info%3Apmid%2F35866378&rft_id=info%3Apmid%2F35866378&rft.externalDocID=35866378 |